US4966577A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prevention of lens-related tissue growth in the eye
Assignee: Allergan Inc
•
Filing: 1988-03-16
•
Granted: 1990-10-30
•
Expires: 2008-03-16
Abstract
Abstract Disclosed is a composition for preventing secondary cataract formation in the eye following removal of the lens, comprising an antibody specific to particular lens cells related to secondary cataract formation, which antibody is conjugated to an antiproliferative agent. The particularly preferred antiproliferative agents require activation after binding of the antibody to the target cells, and activation may be accomplished by addition of a second composition or by exposure of the eye to electromagnetic energy. Also disclosed is a method of using the composition by administering it directly to the site from which the lens was removed to kill or prevent proliferation of lens cells.
Inventors
- 👤 Craig E. Crosson
- 👤 Beverly E. Barton
- 👤 William H. Garner
- 👤 Arlene E. Gwon
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 20:28
CPC Classifications
A; A61; A61K; A61K41/00; A61K41/0057; A61K41/0071; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6835
Claims Analysis
Total Claims: 33
Claim 1
Independent Claim
123 words
A method for preventing tissue growth in the eye following removal of the natural lens, comprising the steps of: providing an antibody specific to proliferative cells in the lens capsular bag and anterior chamber, but not to other eye tissue, wherein said antibody is conjugated to an antiproliferative agent, wherein said antiproliferative agent requires activation in order to prevent proliferation of cells bound by said antibody conjugate; introducing said antibody into the lens capsular bag or anterior chamber of the eye after removal of the natural lens from the eye; permitting said antibody conjugate to bind to proliferative cells in the lens capsular bag or anterior chamber; and activating said proliferative agent after binding said cells to prevent proliferation of said bound cells.
Claim 2
Independent Claim
123 words
A method for preventing tissue growth in the eye following removal of the natural lens, comprising the steps of: providing an antibody specific to proliferative cells in the lens capsular bag and anterior chamber, but not to other eye tissue, wherein said antibody is conjugated to an antiproliferative agent, wherein said antiproliferative agent requires activation in order to prevent proliferation of cells bound by said antibody conjugate; introducing said antibody into the lens capsular bag or anterior chamber of the eye after removal of the natural lens from the eye; permitting said antibody conjugate to bind to proliferative cells in the lens capsular bag or anterior chamber; and activating said proliferative agent after binding said cells to prevent proliferation of said bound cells.
Claim 3
Dependent Claim
41 words
The method of claim 1, wherein said antiproliferative agent is activated by cooperating with a second compound to form an active proliferationpreventative species, and wherein said activating step comprise adding said second compound to said lens capsular bag and interior chamber.
Claim 4
Dependent Claim
35 words
The method of claim 2, wherein said antiproliferative agent is an enzyme and said second compound is a substrate for said enzyme, and wherein action of said enzyme on said substrate generates said proliferation-preventative species.
Claim 5
Dependent Claim
14 words
The method of claim 3, wherein said enzyme is xanthine oxidase or glucose oxidase.
Claim 6
Dependent Claim
37 words
The method of claim 1, wherein said antiproliferative agent requires activation by light in order to prevent proliferation of said bound cells, further comprising the step of: activating said antiproliferative agent with light after binding said cells.
Claim 7
Dependent Claim
23 words
The method of claim 2 or 5, wherein said antiproliferative agent forms an oxidizing moiety after activation to prevent proliferation of said cells.
Claim 8
Dependent Claim
11 words
The method of claim 1, wherein said antibody is polyclonal antibody.
Claim 9
Dependent Claim
11 words
The method of claim 1, wherein said antibody is monoclonal antibody.
Claim 10
Dependent Claim
34 words
The method of claim 6, wherein the light required to activate said antiproliferative agent is light of a certain wavelength, and wherein said activation step comprises directing light of said wavelength into the eye.
Claim 11
Dependent Claim
11 words
The method of claim 5, wherein said antiproliferative agent is hematoporphyrin.
Claim 12
Dependent Claim
18 words
The method of claim 7 or 8, wherein said antibody is specific to lens epithelial cell surface antigen.
Claim 13
Dependent Claim
18 words
The method of claim 7 or 8, wherein said antibody is specific to lens fiber cell surface antigen.
Claim 14
Dependent Claim
15 words
The method of claim 12, wherein said antigen is a protein of about 26,000 daltons.
Claim 15
Dependent Claim
15 words
The method of claim 12, wherein said antigen is a protein of about 70,000 daltons.
Claim 16
Independent Claim
124 words
A method for preventing tissue growth in the eye following removal of the natural lens, comprising the steps of: providing an antibody specific to proliferative cells in the lens capsular bag and anterior chamber but not to other eye tissue, wherein said antibody is conjugated to an antiproliferative agent requiring activation by light in order to prevent proliferation of said cells; introducing said antibody directly into the lens capsular bag and anterior chamber of the eye after removal of the natural lens therefrom; permitting said antibody to bind to proliferative cells in the lens capsular bag and anterior chamber; activating said antiproliferative agent after binding said cells by directing light into the eye; and preventing proliferation of said bound cells with said antiproliferative agent.
Claim 17
Independent Claim
124 words
A method for preventing tissue growth in the eye following removal of the natural lens, comprising the steps of: providing an antibody specific to proliferative cells in the lens capsular bag and anterior chamber but not to other eye tissue, wherein said antibody is conjugated to an antiproliferative agent requiring activation by light in order to prevent proliferation of said cells; introducing said antibody directly into the lens capsular bag and anterior chamber of the eye after removal of the natural lens therefrom; permitting said antibody to bind to proliferative cells in the lens capsular bag and anterior chamber; activating said antiproliferative agent after binding said cells by directing light into the eye; and preventing proliferation of said bound cells with said antiproliferative agent.
Claim 18
Dependent Claim
75 words
A composition for preventing tissue ingrowth into the lens capsule or anterior chamber of the eye following removal of the natural lens, comprising: an antibody that is specific to a cell surface antigen of proliferative cells in the lens capsule or anterior chamber, but not specific to other ocular tissue; and an antiproliferative agent that must be activated in order to exhibit antiproliferative properties conjugated to said antibody for preventing growth of said proliferative cells.
Claim 19
Dependent Claim
75 words
A composition for preventing tissue ingrowth into the lens capsule or anterior chamber of the eye following removal of the natural lens, comprising: an antibody that is specific to a cell surface antigen of proliferative cells in the lens capsule or anterior chamber, but not specific to other ocular tissue; and an antiproliferative agent that must be activated in order to exhibit antiproliferative properties conjugated to said antibody for preventing growth of said proliferative cells.
Claim 20
Dependent Claim
22 words
The composition of claim 16, wherein said antiproliferative agent is activated by cooperating with a second compound to form a proliferation-preventative species.
Claim 21
Dependent Claim
11 words
The composition of claim 16, wherein said antibody is polyclonal antibody.
Claim 22
Dependent Claim
11 words
The composition of claim 16, wherein said antibody is monoclonal antibody.
Claim 23
Dependent Claim
18 words
The composition of claim 18 or 19, wherein said antibody is specific to lens epithelial cell surface antigen.
Claim 24
Dependent Claim
18 words
The composition of claim 18 or 19, wherein said antibody is specific to lens fiber cell surface antigen.
Claim 25
Dependent Claim
15 words
The composition of claim 21, wherein said antigen is a protein of about 26,000 daltons.
Claim 26
Dependent Claim
15 words
The composition of claim 21, wherein said antigen is a protein of about 70,000 daltons.
Claim 27
Dependent Claim
35 words
THe composition of claim 17, wherein said antiproliferative agent is an enzyme and said second compound is a substrate for said enzyme, and wherein action of said enzyme on said substrate generates said proliferation-preventative species.
Claim 28
Dependent Claim
14 words
The composition of claim 26, wherein said enzyme is xanthine oxidase or glucose oxidase.
Claim 29
Dependent Claim
77 words
A composition for preventing tissue ingrowth into the lens capsule or anterior chamber of the eye following removal of the natural lens, comprising: an antibody that is specific to a cell surface antigen of proliferative cells in the lens capsule or anterior chamber, but not specific to other ocular tissue; and an antiproliferative agent, which must be activated by light in order to exhibit antiproliferative properties, conjugated to said antibody for preventing growth of said proliferative cells.
Claim 30
Dependent Claim
77 words
A composition for preventing tissue ingrowth into the lens capsule or anterior chamber of the eye following removal of the natural lens, comprising: an antibody that is specific to a cell surface antigen of proliferative cells in the lens capsule or anterior chamber, but not specific to other ocular tissue; and an antiproliferative agent, which must be activated by light in order to exhibit antiproliferative properties, conjugated to said antibody for preventing growth of said proliferative cells.
Claim 31
Dependent Claim
23 words
The composition of claim 16 or 26, wherein said antiproliferative agent forms an oxidizing moiety to prevent proliferation of said cells after activation.
Claim 32
Dependent Claim
33 words
The composition of claim 26, wherein said antiproliferative agent forms an oxidizing moiety to prevent proliferation of said cells and wherein light of a certain wavelength is required to activate said antiproliferative agent.
Claim 33
Dependent Claim
11 words
The composition of claim 26, wherein said antiproliferative agent is hematoporphyrin.
References Cited (Backward Citations)
US4363758A
Cited
CA1178206A
Cited
US4657930A
Cited
GB2110532A
Cited
US4432751A
Cited
US4665089A
Cited
US4797422A
Cited
US4778828A
Cited
US4871350A
Cited
US4826872A
Cited
US4778815A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-10-29 | 1994-04-30 | 1994-10-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-10-29 | 1998-04-30 | 1998-10-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-10-29 | 2002-04-30 | 2002-10-30 | $7700.00 | Window Closed / Lapsed |